Report Submitted 6/24/2021 to the Vermont Office of the Attorney General for Introduction of a New Prescription Drug to Market
Janssen Biotech, Inc.
Information required pursuant to 18 VSA § 4637(c),(d)
RYBREVANT™

Requirement	Submission - RYBREVANT™
18 VSA § 4637(c)(1) A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	While specific marketing and pricing plans are not available in the public domain, generally we plan to market in the US and promote to appropriate healthcare professionals who treat individuals diagnosed with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion. The pricing plan has WAC set for 350 mg / 7 mL vial at $2,986.43. The list price of RYBREVANT™ is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. RYBREVANT™ will also be discounted as required under the 340B program, Federal Supply Schedule, and other government programs. International approvals are pending.
18 VSA § 4637(c)(2) The estimated volume of patients who may be prescribed the drug	The estimated number of patients in the United States with a condition for which RYBREVANT™ may be prescribed is not in the public domain or publicly available.
18 VSA § 4637(c)(3) Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	The drug was granted breakthrough therapy designation and priority review.
18 VSA § 4637(c)(4) The date and price of acquisition if the drug was not developed by the manufacturer.	Not an acquisition

Note: as provided in 18 VSA § 4637(d), we are limiting the information reported to that which is in the public domain or publicly available